%0 English Abstract
%T [Chinese expert consensus on big data and real world study in cancer research (2022 edition)].
%A  
%J Zhonghua Zhong Liu Za Zhi
%V 44
%N 12
%D Dec 2022 23
%M 36575784
暂无%R 10.3760/cma.j.cn112152-20220628-00458
%X Cancer is a public health and social problem to which great attention should be attached. Not only are there a large number of cancer patients in China, but great differences also exist in etiology, epidemiology, disease spectrum, and treatment between China and western countries. Therefore, tumor-related data in China has its own characteristics. Full reference to the data of western countries cannot accurately reflect the real situation of cancer prevention and treatment in China. If we can integrate, process and analyze Chinese data, and find rules in specific etiology, incidence, drug sensitivity and prognosis, it will play an important role in the formulation of health policy, medical research and disease prevention. The Society of Cancer Big Data and Real World Study of China Anti-Cancer Association organized multidisciplinary experts, combined with domestic and foreign literature and clinical practice, after repeated discussion and revision, finished this consensus including background, analysis and management, direction planning and operation flow, basic design, quality control standards, evidence level classification, data security and privacy standards of big data and real world study. The aim is to take full advantages of Chinese cancer big data to carry out high-quality real world study, and better promote the prevention and treatment of cancer in China.<BR>肿瘤是需要高度重视的公共卫生问题及社会问题。中国肿瘤患者不仅数量众多，而且在病因、流行病学、疾病谱、治疗方式等方面与西方国家存在较大差异。因此，中国肿瘤相关数据具有自己的特点，如果完全参照西方国家数据，则不能正确反映中国肿瘤防治的真实现状。若能整合、处理、分析中国数据，并在特有病因、发病率、药物敏感性、预后等方面找到规律，将对制定卫生政策、医学研究、疾病预防等起到重大作用。中国抗癌协会肿瘤大数据与真实世界研究专业委员会组织多学科专家，结合国内外文献和临床实践，经过反复讨论修改，基于肿瘤大数据与真实世界研究的背景、分析与管理、方向规划与操作流程、基本设计、质量控制标准、证据级别分类、数据安全与隐私标准等方面，最终形成《肿瘤大数据与真实世界研究中国专家共识(2022版)》，旨在发挥中国肿瘤大数据的优势，开展高质量的真实世界研究，更好地推进中国肿瘤防治工作。.